102 related articles for article (PubMed ID: 19025608)
1. Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas.
Matsuo T; Sugita T; Shimose S; Kubo T; Ishikawa M; Yasunaga Y; Ochi M
J Exp Clin Cancer Res; 2008 Nov; 27(1):73. PubMed ID: 19025608
[TBL] [Abstract][Full Text] [Related]
2. PML down-regulation in soft tissue sarcomas.
Vincenzi B; Perrone G; Santini D; Grosso F; Silletta M; Frezza A; Rossi S; Russo A; Rabitti C; Gebbia N; Badalamenti G; Casali P; Muda AO; Dei Tos AP; Tonini G
J Cell Physiol; 2010 Sep; 224(3):644-8. PubMed ID: 20578240
[TBL] [Abstract][Full Text] [Related]
3. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
Vincenzi B; Santini D; Schiavon G; Frezza AM; Silletta M; Crucitti P; Casali P; Dei Tos AP; Rossi S; Rizzo S; Badalamenti G; Tomasino RM; Russo A; Butrynski JE; Tonini G
J Cell Physiol; 2012 Apr; 227(4):1657-62. PubMed ID: 21678421
[TBL] [Abstract][Full Text] [Related]
4. The transcription coactivator CBP is a dynamic component of the promyelocytic leukemia nuclear body.
Boisvert FM; Kruhlak MJ; Box AK; Hendzel MJ; Bazett-Jones DP
J Cell Biol; 2001 Mar; 152(5):1099-106. PubMed ID: 11238464
[TBL] [Abstract][Full Text] [Related]
5. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma.
Nakayama R; Nemoto T; Takahashi H; Ohta T; Kawai A; Seki K; Yoshida T; Toyama Y; Ichikawa H; Hasegawa T
Mod Pathol; 2007 Jul; 20(7):749-59. PubMed ID: 17464315
[TBL] [Abstract][Full Text] [Related]
6. SCANning for PML nuclear bodies with Myeloid Zinc Finger 1.
Gallagher RE
Leuk Res; 2008 Nov; 32(11):1650-2. PubMed ID: 18586322
[No Abstract] [Full Text] [Related]
7. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness.
Yu JH; Nakajima A; Nakajima H; Diller LR; Bloch KD; Bloch DB
Cancer Res; 2004 Feb; 64(3):928-33. PubMed ID: 14871822
[TBL] [Abstract][Full Text] [Related]
8. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA.
Bøe SO; Haave M; Jul-Larsen A; Grudic A; Bjerkvig R; Lønning PE
J Cell Sci; 2006 Aug; 119(Pt 16):3284-95. PubMed ID: 16868026
[TBL] [Abstract][Full Text] [Related]
9. Promyelocytic leukemia-nuclear body formation is an early event leading to retinoic acid-induced differentiation of neuroblastoma cells.
Delaune A; Corbière C; Benjelloun FD; Legrand E; Vannier JP; Ripoll C; Vasse M
J Neurochem; 2008 Jan; 104(1):89-99. PubMed ID: 17986232
[TBL] [Abstract][Full Text] [Related]
10. The mechanisms of PML-nuclear body formation.
Shen TH; Lin HK; Scaglioni PP; Yung TM; Pandolfi PP
Mol Cell; 2006 Nov; 24(3):331-9. PubMed ID: 17081985
[TBL] [Abstract][Full Text] [Related]
11. The translation initiation factor 3 subunit eIF3K interacts with PML and associates with PML nuclear bodies.
Salsman J; Pinder J; Tse B; Corkery D; Dellaire G
Exp Cell Res; 2013 Oct; 319(17):2554-65. PubMed ID: 24036361
[TBL] [Abstract][Full Text] [Related]
12. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
13. Functional proteomic analysis of promyelocytic leukaemia nuclear bodies in irradiation-induced MCF-7 cells.
Liu J; Song Y; Tian B; Qian J; Dong Y; Liu J; Liu B; Sun Z
J Biochem; 2010 Dec; 148(6):659-67. PubMed ID: 20823370
[TBL] [Abstract][Full Text] [Related]
14. Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies.
Adamson AL; Kenney S
J Virol; 2001 Mar; 75(5):2388-99. PubMed ID: 11160742
[TBL] [Abstract][Full Text] [Related]
15. Role and fate of PML nuclear bodies in response to interferon and viral infections.
Regad T; Chelbi-Alix MK
Oncogene; 2001 Oct; 20(49):7274-86. PubMed ID: 11704856
[TBL] [Abstract][Full Text] [Related]
16. Promyelocytic leukemia (PML) nuclear bodies are disorganized in colorectal tumors with total loss of major histocompatibility complex class I expression and LMP7 downregulation.
Cabrera CM; Jiménez P; Concha A; Garrido F; Ruiz-Cabello F
Tissue Antigens; 2004 May; 63(5):446-52. PubMed ID: 15104675
[TBL] [Abstract][Full Text] [Related]
17. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies.
Bernardi R; Pandolfi PP
Nat Rev Mol Cell Biol; 2007 Dec; 8(12):1006-16. PubMed ID: 17928811
[TBL] [Abstract][Full Text] [Related]
18. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients.
Vincenzi B; Santini D; Perrone G; Russo A; Adamo V; Rizzo S; Castri F; Antinori A; Alloni R; Crucitti PF; Morini S; Rabitti C; Vecchio FM; Magistrelli P; Coppola R; Tonini G
Ann Oncol; 2009 Jan; 20(1):78-83. PubMed ID: 18689862
[TBL] [Abstract][Full Text] [Related]
19. Role of the promyelocytic leukemia body in the dynamic interaction between the androgen receptor and steroid receptor coactivator-1 in living cells.
Rivera OJ; Song CS; Centonze VE; Lechleiter JD; Chatterjee B; Roy AK
Mol Endocrinol; 2003 Jan; 17(1):128-40. PubMed ID: 12511612
[TBL] [Abstract][Full Text] [Related]
20. PML protein as a prognostic molecular marker for patients with esophageal squamous cell carcinomas receiving primary surgery.
Yen CC; Tsao YP; Chen PC; Wu YC; Liu JH; Pan CC; Liu CY; Tzeng CH; Chen PM; Chen YJ; Lin CH; Hsu WH
J Surg Oncol; 2011 Jun; 103(8):761-7. PubMed ID: 21240990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
